Abstract

P183 Nivolumab Plus Ipilimumab (NIVO+IPI) vs Sunitinib (SUN) for first-line treatment of advanced Renal Cell Carcinoma (aRCC): Efficacy across number of International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk factors with 8-year follow-up from the phase 3 CheckMate 214 trial

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.